Navigation Links
FDA Mislead On Asthma Drug By GlaxoSmithKline

Charges have been held against, a London based leading drug company, GlaxoSmithKline for having presented incorrect data regarding an anti-asthmatic drug, Serevent to the U.S. Food and Drug Administration two years ago when the // medicine came up for a review. This became evident last November when The FDA identified Serevent as a drug that needed additional warnings.

The Public Citizen Group has registered a case regarding the issue. The company is said to have manipulated from the so-called SMART trial, which was initiated in 1996. The study was conducted on a group of asthma patients for 28 weeks who received either Serevent, also known as salmeterol, or a placebo. An increased risk of asthma-related death in those who had consumed the drug has been documented.

However, Glaxo is said to have misled the FDA when it submitted six months of post- trial data in July 2003, along with the study's actual 28 weeks of data. There is a belief that the data presented is an underestimated projection of the apparent dangers associated with salmeterol, including asthma related death. The SMART data has never been published.

``GlaxoSmithKline did not clearly inform the FDA that the final study included data from six months after the trial had concluded until the FDA inquired about the results in April, 2004,'' according to those who have filed the case.

The company in response has issued a statement stating that the SMART study data were collected and analyzed by an independent clinical research organization, not by them.

“After discussions with the Data Safety Monitoring Board, Glaxo was provided with unmasked results of the interim analysis and subsequently terminated the study. The SMART trial was stopped on Jan. 23, 2003, a “Dear Healthcare Professional letter'' was delivered overnight to all U.S. doctors who had prescribed salmeterol, and notices were posted on both the FDA and Glaxo websites,'' said Mr. Kathy Rick
'"/>




Page: 1 2

Related medicine news :

1. Misleading anti-malarial drug
2. Misleading Advertisements for Prescription Drugs
3. The Effects Of Smoking Misleading
4. Lifting The Screen off Misleading Sunscreen labels
5. Misleading Health Claims On Food Labels No Longer Allowed in EU
6. Walkers Crisps Advertisements make Misleading Claims about Salt Content
7. Medical Council Of India Draws Public Attention on Misleading Ads.
8. Obesity Drug Advertisements Misleading Teens
9. Labeling of Dairy Products with Trans fat labels, Misleading to Consumers
10. New Drug for Bronchial Asthma
11. Asthma may actually be prevented by Dust and Dirt
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA Mislead Asthma Drug GlaxoSmithKline

(Date:9/30/2014)... (PRWEB) September 30, 2014 Glycodrive ... Star Nutraceuticals designed to help maximize lean, strong muscle ... the body’s absorption of glucose has caught the attention ... “The main purpose behind Glycodrive is to help the ... muscle,” reports Michaels. “Carbs are essential in the muscle-building ...
(Date:9/30/2014)... Las Vegas, NV (PRWEB) September 30, 2014 ... that is helping people perform better in and out of ... performance, and memory has caught the attention of Shane Michaels, ... the day-to-day grind, fatigue is the reason most people simply ... want, whether that means staying focused at work, getting the ...
(Date:9/30/2014)... For most families, fall means back-to-school pictures and ... annual festival. For millions of children, fall also means ... infection Enterovirus D68. , While symptoms mimic the ... especially children with weakened immune systems – can develop ... prompting hospitals across the country to enact visitor restrictions. ...
(Date:9/30/2014)... 30, 2014 Regenerative Medicine Solutions (RMS) ... clinics in Nashville, Tennessee. RMS welcomes the launch of ... the expansion of a new treatment center for the ... Sleep Apnea Institute to Nashville, the hope is to ... apnea: both diagnosed and undiagnosed. With Nashville being a ...
(Date:9/30/2014)... Two revolutionary procedures now being utilized by Dr. ... a far less painful and far more effective remedy ... felt electric shock waves surge through your teeth as you ... possible you already know the impact of receding gums,” says ... in West Palm Beach, and a Fellow in the Academy ...
Breaking Medicine News(10 mins):Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:As Hospitals Combat Enterovirus Outbreaks, Patients and Families Turn to “Virtual Visits” with CaringBridge 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3
... , New Report Examines How Reform May Impact ... 17 According to a new report from State Coverage Initiatives, ... issue of how new or modified federal rules will impact health ... the states. , , The report, ...
... vampires, cancer tumors require an ample supply of blood to ... up like raisins and die. To that end, Dr. ... Pharmacology, Sackler School of Medicine, and her team of researchers ... to the tumor. Ferrying a variety of existing life-saving therapies ...
... CA An important analysis conducted by Children,s Hospital ... optimal dietary intakes of vitamin K to prevent age-related ... cardiovascular disease, and possibly cancer (1). Vitamin K is ... Swiss chard, and is either not present or present ...
... , DEL MAR, Calif., Sept. 17 In ... nerve pain said that their pain was one of the top ... that people with diabetic nerve pain recognize the condition,s impact on ... discussed the condition with a healthcare provider, just slightly less than ...
... also found younger adults at higher risk , THURSDAY, Sept. ... more than 8 million adults in the United States seriously ... to contemplate taking their own lives. , In addition to ... a plan to do so, and 1.1 million actually attempted ...
... , , LOUISVILLE, Ky., Sept. ... and AAF products, is proud to announce the MEGAcel(TM) I ... Helior media used in the MEGAcel I ... drop than conventional micro-fiberglass media. With a significantly lower operating resistance, energy consumption ...
Cached Medicine News:Health News:Health Care Reform and American Federalism 2Health News:Killing cancer like a vampire slayer 2Health News:New vitamin K analysis supports the triage theory 2Health News:New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated 2Health News:New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated 3Health News:New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated 4Health News:New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated 5Health News:8.3 Million U.S. Adults Considered Suicide Last Year 2Health News:AAF(R) Announces MEGAcel(TM) I Filter with Helior(TM) Media 2
(Date:9/30/2014)... LEXINGTON, Ky. , Sept. 30, 2014 ... coherence tomography (OCT), offered a new look at the ... to alter how physicians understand and treat the disease, ... study, conducted at Baptist Health Lexington between September 2010 ... issue of the Journal of the American College ...
(Date:9/30/2014)... , Sept. 30, 2014 BioStructures, LLC ... American Association of Tissue Banks (AATB), it was ... Executive Officer. Accreditation follows an intensive ... specially trained AATB inspector.  It establishes that the ... the facility meets or exceeds the standards set ...
(Date:9/30/2014)... 30, 2014 The report based ... Size, Share, Growth and Forecast, 2007 - 2017," elaborated ... USD 20.8 billion in 2012 and is further expected ... a CAGR of 7.3% from 2012 to 2017. ... health purposes, especially to prevent chronic diseases that may ...
Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... June 3, 2007 - Schering-Plough Corp. announced ... maintenance chemotherapy with,Caelyx (pegylated liposomal doxorubicin hydrochloride),significantly ... with,metastatic breast cancer with infrequent and manageable ... presented,today at the 43rd Annual Meeting of ...
... of Largest Ever Phase III Clinical Trial ... /PRNewswire-FirstCall/ --,GlaxoSmithKline today announced final results of ... investigational MAGE-A3,Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3,positive ... Cell Lung Cancer,(NSCLC). These data were presented ...
Cached Medicine Technology:Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 2Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 3Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 4Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 5Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 2Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 3Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 4Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 5Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 6
6 mm tying platform. Round knurled handle with polished finish. Teeth: 0.3 mm, 1 x 2. Orientation: Left hand....
0.12 mm, 1 x 2 teeth set at 45 degrees with 6 mm tying platform. Wide serrated handle with polished finish....
Stainless steel model of the popular Nordan titanium Colibri forceps. Tying platform with 0.12 mm teeth for grasping delicate structures. Flattened round handle with polished finish....
0.12 mm, 1 x 2 teeth set at 45 degrees with 4.5 mm tying platform. Serrated handle with polished finish....
Medicine Products: